taletrectinib
innovent biologics,baoyuan biopharma
['taletrectinib', 'innovent biologics', 'innovent bio', 'innovent', 'innovent_2011']
innovent and anheart jointly present updated phase 2 efficacy and safety data of taletrectinib (ros1-tki) at the 2022 american society of clinical oncology (asco) annual meeting 
To develop and commercialize high-quality biopharmaceuticals that are affordable to ordinary people.